Eisai said Leqembi is on track to reach JPY 143.5 billion ($905 million) in fiscal 2026, up about 63% from JPY 88 billion in fiscal 2025, as blood-based biomarker confirmatory diagnosis and a planned subcutaneous auto-injector help ease key adoption bottlenecks. On the company’s earnings call Friday, CEO Haruo Naito said those two changes are reducing friction around amyloid-beta confirmation and IV infusion burden, supporting what he called the start of full-scale Alzheimer’s market growth.

Why It Matters To Oncology

• For clinicians focused on drug discovery, the Leqembi story is a commercialization case study in how diagnostics and delivery innovation can unlock uptake for high-value specialty therapies.

• The same playbook matters in oncology: better biomarker testing pathways and lower-burden administration can expand access, accelerate treatment starts and improve real-world adoption.

• Eisai’s comments also underscore a broader lesson for precision medicine portfolios: removing workflow bottlenecks may be as important as adding new efficacy data.

The Financials

• Leqembi is forecast to generate JPY 143.5 billion in fiscal 2026, versus JPY 88 billion in fiscal 2025.

• Eisai expects August U.S. regulatory approval for Leqembi IQLIK, its subcutaneous auto-injector formulation, with a parallel Japan launch also planned.

• Companywide sales are projected to rise 7% year over year to JPY 883.5 billion, led primarily by Leqembi and Dayvigo.

• In oncology, Lenvima is expected to grow less than 1% to JPY 345 billion amid generics and pricing pressure; fiscal 2025 sales were JPY 342.5 billion.

What They're Saying

• “Without doubt, BBM and confirmatory diagnosis usage has provided tailwind. We believe that a full-scale growth of the [Alzheimer’s disease] market has started,” Naito said.

• Biogen, Eisai’s Leqembi partner, has also suggested the drug could be used by patients seeking to continue anti-amyloid therapy after completing Eli Lilly’s roughly 18-month Kisunla regimen.

What's Next

• Watch the August FDA decision on Leqembi IQLIK, which could meaningfully reduce infusion-center dependence.

• Also watch whether BBM-based confirmatory diagnosis scales across markets, since broader testing access appears central to Eisai’s growth thesis.

• For oncology drug developers, the key read-through is strategic: companion diagnostics, simpler administration and pathway redesign can materially change launch trajectories.